Endo get preliminary injunction against QuVa Pharma over vasopressin product

2 March 2018
medical_legal_law_big

Ireland-headquartered Endo International (Nasdaq: ENDP), along with its subsidiaries Par Pharmaceutical and Par Sterile Products, have obtained a preliminary injunction preventing QuVa Pharma from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict, the first and only vasopressin injection, USP, product approved by the US Food and Drug Administration.

The preliminary injunction, issued by Brian Martinotti, US District Judge, is effective through the conclusion of a trial, which has not yet been scheduled.

In August 2017, Par filed a complaint against Texas, USA-based QuVa and several individual defendants in the US District Court for the District of New Jersey (Case No. 17-6115) alleging, among other claims, the misappropriation of Par's trade secrets by the defendants in connection with QuVa's development of a bulk compounded vasopressin product.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical